CoChat

Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO ‐2 randomized clinical study

Open access
Gadde, Kishore M., Vetter, Marion L., Iqbal, Nayyar, Hardy, Elise, Öhman, Peter, on behalf of the DURATION‐NEO‐2 study investigators · 2017 · Diabetes, Obesity and Metabolism
Cited by 57

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Aims: Glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors treat type 2 diabetes through incretin‐signaling pathways. This study compared the efficacy and safety of the glucagon‐like peptide‐1 receptor agonist exenatide once‐weekly ( M iglyol) suspension for autoinjection ( QWS‐AI ) with the dipeptidyl peptidase‐4 inhibitor sitagliptin or placebo. Materials and methods: In this open‐label, multicentre study of patients with type 2 diabetes who had suboptimal glycaemic control on metformin monotherapy, 365 patients were randomized to receive exenatide 2.0 mg QWS‐AI , sitagliptin 100 mg once daily or oral placebo (3:2:1 ratio). The primary endpoint was change in glycated hemoglobin ( HbA1c ) from baseline to 28 weeks. Results: At 28 weeks, exenatide QWS‐AI significantly reduced HbA1c from baseline compared to sitagliptin (−1.13% vs −0.75% [baseline values, 8.42% and 8.50%, respectively]; P = .02) and placebo (−0.40% [baseline value, 8.50%]; P = .001). More exenatide QWS‐AI ‐treated patients achieved HbA1c <7.0% than did sitagliptin‐ or placebo‐treated patients (43.1% vs 32.0% and 24.6%; both P < .05). Exenatide QWS‐AI and sitagliptin reduced fasting plasma glucose from baseline to 28 weeks (−21.3 and −11.3 mg/dL) vs placebo (+9.6 mg/dL), with no significant difference between the 2 active treatments. Body weight decreased with both active treatments (−1.12 and −1.19 kg), but not with placebo (+0.15 kg). No improvement in blood pressure was observed in any group. The most common adverse events with exenatide QWS‐AI were gastrointestinal events and injection‐site reactions. Conclusions: This study demonstrated that exenatide QWS‐AI reduced HbA1c more than sitagliptin or placebo and was well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12908

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 57

Metadata

Authors
Gadde, K. M., Vetter, M. L., Iqbal, N., Hardy, E., Öhman, P., & on behalf of the DURATION‐NEO‐2 study investigators
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-03-17
Volume
19
Issue
7
Pages
979-988
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2588441560
Cited by
57
References
5
FWCI
4.45
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO ‐2 randomized clinical study. https://app.cochat.ai/papers/10.1111/dom.12908
The paper
Gadde, K. M., Vetter, M. L., Iqbal, N., Hardy, E., Öhman, P., & on behalf of the DURATION‐NEO‐2 study investigators. (2017). Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO ‐2 randomized clinical study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12908

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.